Literature DB >> 22330909

Crystal structures of KPC-2 β-lactamase in complex with 3-nitrophenyl boronic acid and the penam sulfone PSR-3-226.

Wei Ke1, Christopher R Bethel, Krisztina M Papp-Wallace, Sundar Ram Reddy Pagadala, Micheal Nottingham, Daniel Fernandez, John D Buynak, Robert A Bonomo, Focco van den Akker.   

Abstract

Class A carbapenemases are a major threat to the potency of carbapenem antibiotics. A widespread carbapenemase, KPC-2, is not easily inhibited by β-lactamase inhibitors (i.e., clavulanic acid, sulbactam, and tazobactam). To explore different mechanisms of inhibition of KPC-2, we determined the crystal structures of KPC-2 with two β-lactamase inhibitors that follow different inactivation pathways and kinetics. The first complex is that of a small boronic acid compound, 3-nitrophenyl boronic acid (3-NPBA), bound to KPC-2 with 1.62-Å resolution. 3-NPBA demonstrated a K(m) value of 1.0 ± 0.1 μM (mean ± standard error) for KPC-2 and blocks the active site by making a reversible covalent interaction with the catalytic S70 residue. The two boron hydroxyl atoms of 3-NPBA are positioned in the oxyanion hole and the deacylation water pocket, respectively. In addition, the aromatic ring of 3-NPBA provides an edge-to-face interaction with W105 in the active site. The structure of KPC-2 with the penam sulfone PSR-3-226 was determined at 1.26-Å resolution. PSR-3-226 displayed a K(m) value of 3.8 ± 0.4 μM for KPC-2, and the inactivation rate constant (k(inact)) was 0.034 ± 0.003 s(-1). When covalently bound to S70, PSR-3-226 forms a trans-enamine intermediate in the KPC-2 active site. The predominant active site interactions are generated via the carbonyl oxygen, which resides in the oxyanion hole, and the carboxyl moiety of PSR-3-226, which interacts with N132, N170, and E166. 3-NPBA and PSR-3-226 are the first β-lactamase inhibitors to be trapped as an acyl-enzyme complex with KPC-2. The structural and inhibitory insights gained here could aid in the design of potent KPC-2 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22330909      PMCID: PMC3346646          DOI: 10.1128/AAC.06099-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Difference density quality (DDQ): a method to assess the global and local correctness of macromolecular crystal structures.

Authors:  F van den Akker; W G Hol
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-01-01

2.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

Review 3.  Emerging carbapenemases: a global perspective.

Authors:  Timothy R Walsh
Journal:  Int J Antimicrob Agents       Date:  2010-11       Impact factor: 5.283

4.  The deacylation mechanism of AmpC beta-lactamase at ultrahigh resolution.

Authors:  Yu Chen; George Minasov; Tomer A Roth; Fabio Prati; Brian K Shoichet
Journal:  J Am Chem Soc       Date:  2006-03-08       Impact factor: 15.419

5.  Ligand-dependent disorder of the Omega loop observed in extended-spectrum SHV-type beta-lactamase.

Authors:  Jared M Sampson; Wei Ke; Christopher R Bethel; S R R Pagadala; Michael D Nottingham; Robert A Bonomo; John D Buynak; Focco van den Akker
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

Review 6.  Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance.

Authors:  Neil Woodford; Jane F Turton; David M Livermore
Journal:  FEMS Microbiol Rev       Date:  2011-03-01       Impact factor: 16.408

7.  Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.

Authors:  Krisztina M Papp-Wallace; Christopher R Bethel; Anne M Distler; Courtney Kasuboski; Magdalena Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

8.  Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.

Authors:  Daniel J Wolter; Philip M Kurpiel; Neil Woodford; Marie-France I Palepou; Richard V Goering; Nancy D Hanson
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

9.  Detection of KPC in Acinetobacter spp. in Puerto Rico.

Authors:  Iraida E Robledo; Edna E Aquino; María I Santé; Jorge L Santana; Diana M Otero; Carlos F León; Guillermo J Vázquez
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  21 in total

Review 1.  A Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes.

Authors:  Alain Philippon; Patrick Slama; Paul Dény; Roger Labia
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

2.  Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.

Authors:  Krisztina M Papp-Wallace; Nhu Q Nguyen; Michael R Jacobs; Christopher R Bethel; Melissa D Barnes; Vijay Kumar; Saralee Bajaksouzian; Susan D Rudin; Philip N Rather; Satish Bhavsar; Tadiparthi Ravikumar; Prasad K Deshpande; Vijay Patil; Ravindra Yeole; Sachin S Bhagwat; Mahesh V Patel; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2018-04-20       Impact factor: 7.446

3.  Influence of substrates and inhibitors on the structure of Klebsiella pneumoniae carbapenemase-2.

Authors:  Ben A Shurina; Richard C Page
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-04

4.  Structure-based approach for identification of novel phenylboronic acids as serine-β-lactamase inhibitors.

Authors:  Jacopo Sgrignani; Filomena De Luca; Hayarpi Torosyan; Jean-Denis Docquier; Da Duan; Beatrice Novati; Fabio Prati; Giorgio Colombo; Giovanni Grazioso
Journal:  J Comput Aided Mol Des       Date:  2016-09-08       Impact factor: 3.686

5.  Crystal Structures of KPC-2 and SHV-1 β-Lactamases in Complex with the Boronic Acid Transition State Analog S02030.

Authors:  Nhu Q Nguyen; Nikhil P Krishnan; Laura J Rojas; Fabio Prati; Emilia Caselli; Chiara Romagnoli; Robert A Bonomo; Focco van den Akker
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

6.  Rapid ertapenem susceptibility testing and Klebsiella pneumoniae carbapenemase phenotype detection in Klebsiella pneumoniae isolates by use of automated microscopy of immobilized live bacterial cells.

Authors:  Carey-Ann D Burnham; Rachel A Frobel; Monica L Herrera; Brian L Wickes
Journal:  J Clin Microbiol       Date:  2014-01-03       Impact factor: 5.948

7.  Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276.

Authors:  Krisztina M Papp-Wallace; Magdalena A Taracila; Kerri M Smith; Yan Xu; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

Review 8.  Carbapenem-Resistant Enterobacteriaceae.

Authors:  Alina Iovleva; Yohei Doi
Journal:  Clin Lab Med       Date:  2017-03-11       Impact factor: 1.935

Review 9.  New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.

Authors:  Sarah M Drawz; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

10.  Local Interactions with the Glu166 Base and the Conformation of an Active Site Loop Play Key Roles in Carbapenem Hydrolysis by the KPC-2 β-lactamase.

Authors:  Ian M Furey; Shrenik C Mehta; Banumathi Sankaran; Liya Hu; B V Venkataram Prasad; Timothy Palzkill
Journal:  J Biol Chem       Date:  2021-05-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.